SANGAMO THERAPEUTICS, INC Collaboration Agreements
12 Contracts & Agreements
- Collaboration and License (Filed With SEC on November 4, 2020)
- Amendment No. 2 to Research Collaboration and License Agreement between the Company and Pfizer Inc., dated July 21, 2020 (Filed With SEC on November 4, 2020)
- Collaboration and License Agreement among the Company, Biogen MA, Inc. and Biogen International GmbH, dated February 26, 2020 (Filed With SEC on May 11, 2020)
- Letter Amendment, dated December 17, 2019, to the Collaboration and License Agreement between the Company and Pfizer Inc., dated May 10, 2017 (Filed With SEC on February 28, 2020)
- Amended and Restated Collaboration and License Agreement between the Company and Kite Pharma, Inc., dated as of September 11, 2019 (Filed With SEC on November 6, 2019)
- Amendment No. 1 to Research Collaboration and License Agreement between the Company and Pfizer., dated December 27, 2017, dated as of March 21, 2019 (Filed With SEC on May 8, 2019)
- Collaboration and License Agreement between the Company and Kite Pharma, Inc., dated February 20, 2018 (Filed With SEC on May 10, 2018)
- Research Collaboration and License Agreement between the Company and Pfizer Inc., dated December 28, 2017 (Filed With SEC on March 1, 2018)
- Collaboration and License Agreement between Sangamo Therapeutics, Inc. and Pfizer, Inc., dated May 10, 2017 (Filed With SEC on August 9, 2017)
- AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT Between SANGAMO BIOSCIENCES, INC. And SHIRE INTERNATIONAL GMBH *** CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH... (Filed With SEC on October 30, 2015)
- GLOBAL RESEARCH, DEVELOPMENT AND COMMERCIALIZATION COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on May 7, 2014)
- COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on February 23, 2012)
